
IMBRUVICA® for Previously Treated cGVHD
IMBRUVICA® (ibrutinib) is an Oral, Once-Daily cGVHD Medication That May Help When Other Systemic Therapies Have Failed
IMBRUVICA® is the first FDA-approved therapy for adult cGVHD patients who have already been treated with other systemic therapies
Now patients who aren’t getting results with steroid therapy have another option1
-
In a trial of previously treated patients, 2 out of 3 patients (28 of 42 patients enrolled in the study) had a response with IMBRUVICA®, which means they showed improvement1
-
Almost half of patients (20 of 42) in the trial had a response to IMBRUVICA® that lasted for at least 20 weeks
What should I know about IMBRUVICA® side effects?
IMBRUVICA® may cause serious side effects, including1:
-
Bleeding problems (hemorrhage)
-
High blood pressure (hypertension)
-
Infections
-
Second primary cancers
-
Decrease in blood cell counts
-
Tumor lysis syndrome*
-
Heart problems: serious heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter) and heart failure
*TLS is a disorder caused by the breakdown products of cancer cell, which can lead to kidney failure and other abnormalities.
The most common side effects in the cGVHD clinical trial were1:
-
Tiredness
-
Muscle spasms
-
Bruising
-
Nausea
-
Diarrhea
-
Bleeding (Hemorrhage)
-
Low platelet counts
-
Low red blood cell count
-
Mouth sores (stomatitis)
-
Pneumonia
In the cGVHD clinical trial, nearly 1 in 4 of patients stopped taking IMBRUVICA® because of side effects.1
This is not a complete list of side effects. Others may occur. Tell your doctor if you think you are experiencing side effects.
References:
- IMBRUVICA® (ibrutinib) Prescribing Information.